Hematologic toxicity/parameters
thrombocytopenia, anemia
EVENTS, THROMBOCYTOPENIA, ANEMIA
The most common adverse hematologic events were anemia (all grades, 42.0%) and thrombocytopenia (all grades, 29.1%; Table Median hemoglobin levels decreased initially upon RUX treatment but subsequently stabilized or even returned to their initial values (from 11.1 g/dL at baseline to 9.8 g/dL at Month 2 and 11.0 g/dL at the end of the study; Median WBC count decreased during RUX treatment from 13.3 × 10During RUX treatment, the median number of platelets initially decreased from 287 × 10